These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
565 related articles for article (PubMed ID: 11751400)
1. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400 [TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
3. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Kikuchi T; Miyazawa N; Moore MA; Crystal RG Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803 [TBL] [Abstract][Full Text] [Related]
4. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Pérez-Díez A; Butterfield LH; Li L; Chakraborty NG; Economou JS; Mukherji B Cancer Res; 1998 Dec; 58(23):5305-9. PubMed ID: 9850054 [TBL] [Abstract][Full Text] [Related]
5. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996 [TBL] [Abstract][Full Text] [Related]
6. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318 [TBL] [Abstract][Full Text] [Related]
14. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. Hao S; Yuan J; Xiang J J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150 [TBL] [Abstract][Full Text] [Related]
15. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism. Steitz J; Brück J; Knop J; Tüting T Gene Ther; 2001 Aug; 8(16):1255-63. PubMed ID: 11509959 [TBL] [Abstract][Full Text] [Related]
16. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827 [TBL] [Abstract][Full Text] [Related]
17. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356 [TBL] [Abstract][Full Text] [Related]
18. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380 [TBL] [Abstract][Full Text] [Related]
19. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088 [TBL] [Abstract][Full Text] [Related]
20. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Ribas A; Butterfield LH; Hu B; Dissette VB; Meng WS; Koh A; Andrews KJ; Lee M; Amar SN; Glaspy JA; McBride WH; Economou JS Cancer Res; 2000 Apr; 60(8):2218-24. PubMed ID: 10786687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]